Rigel Pharmaceuticals (FRA:RI2) Short Interest


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
78 GF Score
Price €29.47
GF Value €23.45
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:RI2 vs CBIO, TRAX, GYRE: Short Interest Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Short Interest falls into.


FRA:RI2
78GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €29.47 is trading 25.7% above its estimated GF Value™ of €23.45.

Key valuation signals for FRA:RI2:

  • Short Interest:
  • GF Value™: €23.45 vs. price of €29.47 (25.7% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score

Get the complete analysis for FRA:RI2

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.47
Price
€23.45
GF Value